{"database":"panorama","file_versions":[],"scores":null,"additional":{"omics_type":["Proteomics"],"submitter":["Marketa Nezvedova"],"species":["Homo Sapiens"],"full_dataset_link":["https://panoramaweb.org/EOPVWs.url"],"submitter_email":["marketa.nezvedova@recetox.muni.cz"],"submitter_affiliation":["RECETOX, Faculty of Science, MUNI"],"sample_protocol":[""],"repository":["PanoramaPublic"],"data_protocol":[""],"additional_accession":[]},"is_claimable":false,"name":"Comparing the Effects of Taurine and 3-Sulfopropanoic Acid, a Metabolite of Tramiprosate, on ApoE4 Pathological Aggregation: Implications for Alzheimer's Disease","description":"Apolipoprotein E4 (ApoE4) is a major genetic risk factor for Alzheimer's disease. Its pathological aggregation can be mitigated by tramiprosate and its metabolite 3-sulfopropanoic acid, along with their impact on the transcription of genes, expression of proteins, and production of lipids. Taurine is a close chemical analogue of tramiprosate with an extra carbon atom, demonstrating protective effects against aging. Using an integrated approach involving static light scattering, hydrogen-deuterium exchange mass spectrometry, molecular dynamics, and studies of cerebral organoids, we evaluated the effects of 3-sulfopropanoic acid and taurine on ApoE4 aggregation, as well as their impact on organoid transcriptomics and proteomics. Our results reveal that taurine effectively inhibits ApoE4 aggregation, comparable to 3-sulfopropanoic acid, and ameliorates the pathophysiological phenotype of ApoE4 in cerebral organoids, aligning it more closely with the ApoE3 phenotype. These findings suggest that taurine may have potential as a therapeutic agent against Alzheimer's disease, particularly in ApoE4/E4 carriers.","dates":{"publication":"Thu Jul 02 00:00:00 GMT+01:00 2026"},"accession":"PXD059743","cross_references":{"TAXONOMY":["9606"]}}